Tian'an Pharmaceutical Co Ltd
Tian'an Pharmaceutical Co., Ltd. develops, manufactures, and sells traditional Chinese herbal medicines, including pallets, hard capsules, and soft ointments for the treatment and prevention of diseases in China. It also engages in the research and development of biology goods and health care products. The company's pharmaceutical and nutraceutical products include Compound Ginseng capsule, a Chi… Read more
Tian'an Pharmaceutical Co Ltd (TNPH) - Net Assets
Latest net assets as of December 2024: $-85.65K USD
Based on the latest financial reports, Tian'an Pharmaceutical Co Ltd (TNPH) has net assets worth $-85.65K USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.71K) and total liabilities ($91.36K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-85.65K |
| % of Total Assets | -1500.26% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -101.0% |
| Growth Volatility | 296.54 |
Tian'an Pharmaceutical Co Ltd - Net Assets Trend (2004–2024)
This chart illustrates how Tian'an Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tian'an Pharmaceutical Co Ltd (2004–2024)
The table below shows the annual net assets of Tian'an Pharmaceutical Co Ltd from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-85.65K | -30.95% |
| 2023-12-31 | $-65.41K | +67.47% |
| 2022-12-31 | $-201.07K | -59.69% |
| 2021-12-31 | $-125.91K | +15.62% |
| 2020-12-31 | $-149.23K | -30.73% |
| 2019-12-31 | $-114.15K | -724.67% |
| 2018-12-31 | $18.27K | -99.87% |
| 2007-12-31 | $14.53 Million | +38.40% |
| 2006-12-31 | $10.50 Million | +23.10% |
| 2005-12-31 | $8.53 Million | +54.44% |
| 2004-12-31 | $5.52 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tian'an Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9901.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $800.00K | % |
| Other Components | $6.72 Million | % |
| Total Equity | $-85.65K | 100.00% |
Tian'an Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Tian'an Pharmaceutical Co Ltd ranked by their market capitalization.
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tian'an Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -70,504 to -85,650, a change of -15,146.
- Net loss of 1,412 reduced equity.
- Other comprehensive income decreased equity by 13,734.
- Other factors decreased equity by 0.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.41K | -1.65% |
| Other Comprehensive Income | $-13.73K | -16.04% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Tian'an Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $0.39 | $0.00 | x |
| 2005-12-31 | $0.61 | $0.00 | x |
| 2006-12-31 | $0.74 | $0.00 | x |
| 2007-12-31 | $0.45 | $0.00 | x |
| 2018-12-31 | $0.00 | $0.00 | x |
| 2019-12-31 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
| 2024-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tian'an Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-6.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 1.79% | 16.12% | 0.10x | 1.06x | $-453.55K |
| 2005 | 10.81% | 26.18% | 0.38x | 1.08x | $68.76K |
| 2006 | 14.62% | 21.49% | 0.64x | 1.07x | $480.17K |
| 2007 | 21.78% | 29.51% | 0.69x | 1.07x | $1.70 Million |
| 2018 | -124.36% | 0.00% | 0.00x | 1.08x | $-24.55K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-102.74K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-65.15K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.46K |
| 2022 | 0.00% | -272.65% | 1.01x | 0.00x | $-341.80 |
| 2023 | 0.00% | -11.22% | 0.40x | 0.00x | $-8.98K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $7.15K |
Industry Comparison
This section compares Tian'an Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tian'an Pharmaceutical Co Ltd (TNPH) | $-85.65K | 1.79% | N/A | $17.24 |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |